ACEA Therapeutics is committed to develop and deliver novel medicines designed to improve the lives of patients with chronic and life-threatening diseases. Our team’s passion for innovation is driven by our deep commitment to discover and develop products that give patients hope for a longer, healthier, and happier life.
Our proven proprietary drug discovery platform has led to the discovery of multiple targeted therapies, which we have advanced into human clinical studies, including Abivertinib, for the treatment of non-small cell lung cancer (NSCLC), and AC0058, for the treatment of autoimmune diseases. With a growing pipeline of novel and proprietary drug candidates, ACEA is well-positioned to continually bring much-needed targeted therapies to patients worldwide.
We are a privately held, fully-integrated pharmaceutical company, headquartered in San Diego, CA operating two subsidiaries in China, ACEA Pharmaceuticals (Quzhou) and ACEA Pharma Research (Hangzhou).
We have recently submitted an NDA to the CFDA for Abivertinib and plan to launch our first product in China in 2019.
Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou and Hong Kong. In 2016, Qiming raised a US healthcare fund, and set up Qiming US office in Seattle. Currently Qiming manages five US Dollar funds and four RMB funds with US$2.7 billion assets under management.